JP2021518366A5 - - Google Patents
Info
- Publication number
- JP2021518366A5 JP2021518366A5 JP2020549740A JP2020549740A JP2021518366A5 JP 2021518366 A5 JP2021518366 A5 JP 2021518366A5 JP 2020549740 A JP2020549740 A JP 2020549740A JP 2020549740 A JP2020549740 A JP 2020549740A JP 2021518366 A5 JP2021518366 A5 JP 2021518366A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- cell
- disorders
- compound according
- alkyl
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023052481A JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841010656 | 2018-03-22 | ||
| IN201841010656 | 2018-03-22 | ||
| PCT/IB2019/052252 WO2019180631A1 (en) | 2018-03-22 | 2019-03-20 | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Division JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518366A JP2021518366A (ja) | 2021-08-02 |
| JPWO2019180631A5 JPWO2019180631A5 (https=) | 2022-03-29 |
| JP2021518366A5 true JP2021518366A5 (https=) | 2022-03-29 |
| JP7254094B2 JP7254094B2 (ja) | 2023-04-07 |
Family
ID=67986029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549740A Active JP7254094B2 (ja) | 2018-03-22 | 2019-03-20 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11542275B2 (https=) |
| EP (1) | EP3768671B1 (https=) |
| JP (2) | JP7254094B2 (https=) |
| KR (1) | KR102767362B1 (https=) |
| CN (1) | CN112105609A (https=) |
| AU (1) | AU2019237329B2 (https=) |
| BR (1) | BR112020019111A2 (https=) |
| CA (1) | CA3092770A1 (https=) |
| CU (1) | CU24627B1 (https=) |
| EA (1) | EA202092253A1 (https=) |
| ES (1) | ES2982859T3 (https=) |
| IL (1) | IL277518B2 (https=) |
| MX (1) | MX2020009738A (https=) |
| MY (1) | MY203159A (https=) |
| PH (1) | PH12020551494A1 (https=) |
| SG (1) | SG11202008526VA (https=) |
| WO (1) | WO2019180631A1 (https=) |
| ZA (1) | ZA202006137B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768670A4 (en) * | 2018-03-22 | 2021-11-24 | Aurigene Discovery Technologies Limited | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| CN115232147B (zh) * | 2022-08-09 | 2023-10-13 | 南方科技大学 | 一种作为HIF-2α激动剂的杂环衍生物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69729583T2 (de) * | 1996-04-17 | 2005-06-09 | Bristol-Myers Squibb Pharma Co. | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren |
| UY32730A (es) * | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| AU2012249421B9 (en) * | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
| IN2012CH00067A (https=) * | 2012-01-06 | 2017-08-04 | ||
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9611257B2 (en) * | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| JP6510485B2 (ja) | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| GB201604027D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| EP3266784A1 (en) | 2016-06-08 | 2018-01-10 | Pierre Fabre Medicament | Protein arginine n-methyltransferases inhibitors and uses thereof |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
-
2019
- 2019-03-20 EP EP19771397.7A patent/EP3768671B1/en active Active
- 2019-03-20 SG SG11202008526VA patent/SG11202008526VA/en unknown
- 2019-03-20 CN CN201980029962.0A patent/CN112105609A/zh active Pending
- 2019-03-20 CA CA3092770A patent/CA3092770A1/en active Pending
- 2019-03-20 WO PCT/IB2019/052252 patent/WO2019180631A1/en not_active Ceased
- 2019-03-20 BR BR112020019111-6A patent/BR112020019111A2/pt unknown
- 2019-03-20 US US16/982,800 patent/US11542275B2/en active Active
- 2019-03-20 EA EA202092253A patent/EA202092253A1/ru unknown
- 2019-03-20 AU AU2019237329A patent/AU2019237329B2/en active Active
- 2019-03-20 MY MYPI2020004843A patent/MY203159A/en unknown
- 2019-03-20 IL IL277518A patent/IL277518B2/en unknown
- 2019-03-20 JP JP2020549740A patent/JP7254094B2/ja active Active
- 2019-03-20 CU CU2020000067A patent/CU24627B1/es unknown
- 2019-03-20 MX MX2020009738A patent/MX2020009738A/es unknown
- 2019-03-20 KR KR1020207030078A patent/KR102767362B1/ko active Active
- 2019-03-20 ES ES19771397T patent/ES2982859T3/es active Active
-
2020
- 2020-09-17 PH PH12020551494A patent/PH12020551494A1/en unknown
- 2020-10-02 ZA ZA2020/06137A patent/ZA202006137B/en unknown
-
2023
- 2023-03-28 JP JP2023052481A patent/JP2023082088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518366A5 (https=) | ||
| JP2025023997A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| JPWO2019180631A5 (https=) | ||
| EP3632907B1 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| ES2665073T3 (es) | Inhibidores de serina/treonina cinasa | |
| WO2019223766A1 (zh) | 一种fgfr抑制剂、其制备方法和在药学上的应用 | |
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| JP2019535744A5 (https=) | ||
| ES2908938T3 (es) | Nuevos derivados de benzamida como moduladores de PPAR-gamma | |
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| JP2013522292A5 (https=) | ||
| CA2736177A1 (en) | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | |
| TW201806593A (zh) | 含有ｅｐ拮抗藥與免疫核查點阻礙藥而成之組合 | |
| EP3632906B1 (en) | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | |
| Robarge et al. | Structure based design of novel 6, 5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo [1, 5-a] pyrazine G-479 | |
| JP2010538091A5 (https=) | ||
| MX2010013699A (es) | Derivados de azacarbolinas, su preparacion y su uso terapeutico. | |
| CN110563703A (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
| JP2017524013A5 (https=) | ||
| JP2023533350A (ja) | 脳透過性ｂｔｋ又はｈｅｒ２阻害剤としての化合物およびその製造方法と応用 | |
| JPWO2019241271A5 (https=) | ||
| KR101739083B1 (ko) | 세포 증식성 질환 치료용 플래티넘 화합물, 그 제조방법 및 용도 | |
| CN113646299A (zh) | 作为前列腺素e2(pge2)受体调节剂的新型n-苄基-2-苯氧基苯甲酰胺衍生物 | |
| WO2021218319A1 (zh) | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 | |
| CN103450133A (zh) | 具有抗肿瘤活性的东莨菪素衍生物、其制备方法及用途 |